Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a
clinical stage vaccine company, today reported positive results from a Phase I
clinical study of the Company's cancer vaccine, DPX-Survivac, for the treatment
of ovarian cancer. The analysis, which now includes all patients enrolled in the
study, confirmed previously reported results and uncovered new findings which
are highlighted as follows:




--  All patients receiving the DPX-Survivac combination therapy who were
    evaluable by tetramer staining (n=10) produced survivin-specific CD8 T
    cells following one or two vaccinations. Importantly the CD8 responses
    were maintained with booster vaccinations. The activation and
    maintenance of these specific immune cells is of particular interest in
    immunotherapy since CD8 T cells are implicated in identifying cancer
    cells, infiltrating tumors and killing cancer targets. 
    
--  All patients receiving the DPX-Survivac combination therapy (n=12)
    demonstrated antigen specific immune responses as measured by at least
    one of the study's three immune monitoring assays (ELISpot, tetramer
    analysis and multiparametric intracellular cell staining). In 11 of 12
    patients, the immune responses were confirmed by two assays (five
    patients) or three assays (six patients) performed. These immune
    responses were established with one or two vaccinations and further
    increased or maintained with follow-up booster vaccinations. 
    
--  Analysis of immune responses by ELISpot showed that a cohort of patients
    receiving the higher dose of the vaccine therapy produced an average
    stimulation factor of greater than 600 times (600x) over baseline
    following their third vaccination. For one of these patients, the
    stimulation factor reached greater than 1,200 times (1,200x) over
    baseline.
    
    These immune responses are in agreement with the previously reported
    average increase of 350 times (350x) over baseline for these same
    patients following their second vaccination. 
    
--  DPX-Survivac was deemed well tolerated with no significant systemic
    adverse events reported in any patients recruited in this study.
    Reported adverse events were restricted to injection site reactions,
    which were experienced by the majority of patients after repeated
    vaccinations. Those patients presenting the strongest immune responses
    were more likely to exhibit more pronounced injection site reactions.
    There were no dose limiting toxicities experienced during the trial and
    no patient withdrew consent due to adverse events. 



"Our clinical trial data has identified a treatment cohort that consistently
produces strong CD8 T cell responses that are clearly detected in the
circulation of vaccinated patients," said Marc Mansour, chief science officer of
Immunovaccine. "The fact that DPX-Survivac is able to generate and maintain the
desired tumor killing T cells provides strong fundamentals for advancing the
clinical development of this novel vaccine."


The Phase I DPX-Survivac trial was a multi-center, open-label, dose-ranging
study in previously diagnosed ovarian cancer patients who had been treated by
surgery and chemotherapy. Under the study protocol, these patients each received
a total of three DPX-Survivac vaccinations three weeks apart with a total of 18
ovarian cancer patients completing all three vaccinations. A lead-in cohort of
three patients received DPX-Survivac alone to confirm the safety of the vaccine
as a monotherapy. Two additional cohorts of six patients each received a low
dose or a high dose of DPX-Survivac in combination with a low dose of
cyclophosphamide. The trial's primary objective was to evaluate the safety of
the vaccine and in combination with cyclophosphamide. A secondary endpoint was
the evaluation of the immune response produced by the vaccine therapy. 


The Phase I study is part of a Phase I/II trial cleared by the U.S. FDA and
Health Canada. The Phase II portion of the trial will be a randomized,
double-blinded, placebo-controlled study with a vaccine dose selected based on
the Phase I results. The Phase II trial will assess the clinical benefit of
DPX-Survivac in patients with advanced ovarian cancer.


The positive results in the company's cancer vaccine program follow immediately
on the heels of the Company's announcement of similarly strong results from its
infectious disease program. Last week, Immunovaccine announced that data from an
immunogenicity study of anthrax vaccines formulated in the Company's DepoVax(TM)
adjuvanting platform showed DepoVax-based vaccines provided a more rapid and
long lasting immune response as compared to the licensed anthrax vaccine
BioThrax(TM). The two studies both leveraged the same DepoVax platform to
enhance immune response sharply in different vaccines targeting different
indications. 


"We're encouraged that the data continues to accumulate showing IMV's technology
can speed up immune responses and make them stronger and longer lasting, for a
wide range of vaccines," said John Trizzino, chief executive officer of
Immunovaccine. "Whether in cancer immunotherapy or in protection against
infectious disease, the results are very positive."


About DPX-Survivac 

DPX-Survivac consists of survivin-based peptide antigens formulated in the
DepoVax(TM) adjuvanting platform. Survivin has been recognized by the National
Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of
its therapeutic potential and its cancer specificity. Survivin is broadly
over-expressed in multiple cancer types in addition to ovarian cancer, including
breast, colon and lung cancers. Survivin plays an essential role in antagonizing
apoptosis, supporting tumor-associated angiogenesis, and promoting resistance to
various anti-cancer therapies. Survivin is also a prognostic factor for many
cancers and it is found in a higher percentage of tumors than other TAA's.


The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell
immune response against cells presenting survivin peptides on HLA class I
molecules. This targeted therapy attempts to use the immune system to actively
and specifically search for and destroy tumor cells. Survivin-specific T-cells
have been shown to target and kill survivin-expressing cancer cells while
sparing normal cells.


About DepoVax 

DepoVax(TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax platform possesses impressive flexibility, allowing
it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About Immunovaccine 

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax-based cancer vaccines into Phase
I human clinical trials. The Company is also advancing a broad infectious
disease pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Pfizer Animal Health. Connect at www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release. 



FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Dr. Marc Mansour
Chief Science Officer
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com


Vida Communication (media)
Tim Brons
(415) 675-7402
tbrons@vidacommunication.com


Vida Communication (investors)
Stephanie Diaz
(415) 675-7401
sdiaz@vidacommunication.com


Brisco Capital Partners (Canadian investors)
Scott Koyich
(403) 262-9888
skoyich@briscocapital.com